ProQR Announces Upcoming Investor Conferences in April and May

Rhea-AI Summary

ProQR Therapeutics NV (Nasdaq: PRQR) announced its participation in several upcoming investor conferences to discuss its innovative RNA therapies using the Axiomer® RNA editing technology platform. Key events include:

• Van Lanschot Kempen Life Sciences Conference – April 26, Amsterdam (1x1 meetings only)
• JMP Securities Life Sciences Conference – May 16, New York (Fireside chat at 12:30 PM EDT)
• Stifel 2023 Tailoring Genes: Genetic Medicines Day – May 30, Virtual (Fireside chat, time TBC)

Details on presentations and webcasts will be available on the company’s website. ProQR is focused on advancing RNA therapies that address both rare and common diseases, utilizing its unique Axiomer® technology for precise RNA editing.

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company management will participate in the following upcoming investor conferences and events.

• Van Lanschot Kempen Life Sciences Conference – Amsterdam
  Wednesday, April 26 – 1x1 meetings only
  
  
• JMP Securities Life Sciences Conference – New York
  Tuesday, May 16, 12:30-12:50pm EDT – Fireside chat and 1x1 meetings
  
  
• Stifel 2023 Tailoring Genes: Genetic Medicines Day – Virtual
  Tuesday, May 30, time TBC – Fireside chat only
  
  

Where applicable, presentation and webcast details will be accessible from the “Investors & Media” section of ProQR’s website under “Events”. Archived webcasts will be available for approximately 30 days following the presentation date.

About Axiomer^®

ProQR is pioneering a next-generation RNA base editing technology called Axiomer^®, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer^® “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer^® EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer^®, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in these conferences, our business, our technology, our strategy, our Axiomer platform, and our product candidates and their therapeutic potential. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; and general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.

Investor contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
hans@lifesciadvisors.com

Media contact:
Robert Stanislaro
FTI Consulting
T: +1 212 850 5657
robert.stanislaro@fticonsulting.com

FAQ

What conferences will ProQR Therapeutics attend in April and May 2023?

ProQR Therapeutics will participate in the Van Lanschot Kempen Life Sciences Conference on April 26, the JMP Securities Life Sciences Conference on May 16, and the Stifel 2023 Tailoring Genes: Genetic Medicines Day on May 30, 2023.

What is the focus of ProQR Therapeutics' Axiomer platform?

ProQR Therapeutics' Axiomer platform focuses on transformative RNA therapies using RNA editing technology to correct disease-causing mutations and modulate protein expression.

When is ProQR's fireside chat at the JMP Securities Conference scheduled?

ProQR's fireside chat at the JMP Securities Life Sciences Conference is scheduled for May 16, 2023, at 12:30 PM EDT.

Where can I find more information about ProQR Therapeutics' investor events?

More information about ProQR Therapeutics' investor events can be found in the 'Investors & Media' section on their official website.

What is the potential of the Axiomer technology developed by ProQR?

The Axiomer technology developed by ProQR has the potential to create a new class of medicines that address a variety of diseases through precise RNA editing.